DiaMedica Therapeutics Inc. (DMAC)
| Market Cap | 78.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.29M |
| Shares Out | 18.79M |
| EPS (ttm) | -0.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 263,596 |
| Open | 4.09 |
| Previous Close | 4.05 |
| Day's Range | 3.95 - 4.24 |
| 52-Week Range | 3.00 - 10.88 |
| Beta | 2.44 |
| Analysts | Strong Buy |
| Price Target | 22.50 (+438.3%) |
| Est. Earnings Date | Nov 3, 2021 |
About DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeu...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price forecast is 22.50, which is an increase of 438.28% from the latest price.
News
DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study
DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurren...
DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...
DiaMedica Therapeutics to Participate at Upcoming Investor Conferences
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...
DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results and Provide a Business Update August 12, 2021
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...
DiaMedica Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...
New Strong Sell Stocks for July 21st
CNO, CLOV, DMAC, HCAT and IMAX have been added to the Zacks Rank #5 (Strong Sell) List on July 21, 2021.
DiaMedica Therapeutics Elects Two Industry Veterans to Its Board of Directors
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...
Moving Average Crossover Alert: DiaMedica Therapeutics (DMAC)
DiaMedica Therapeutics (DMAC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
DiaMedica Therapeutics Stock Slips On Mixed DM199 Data In Chronic Kidney Disease Patients
DiaMedica Therapeutics Inc (NASDAQ: DMAC) has announced positive interim results from its Phase 2 REDUX trial of DM199 in chronic kidney disease (CKD). The trial is designed to evaluate the effect of D...
DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal di...
Is the Options Market Predicting a Spike in DiaMedica (DMAC) Stock?
Investors need to pay close attention to DiaMedica (DMAC) stock based on the movements in the options market lately.
DiaMedica Stock Gains On Green Signal To Start Pivotal DM199 Trial In Ischemic Stroke
The FDA has signed off DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Investigational New Drug (IND) application to proceed with a pivotal Phase 2/3 study of DM199 (recombinant human tissue kallikrein-1or ...
DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for ...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical Company focused on developing novel treatments for neurological disorders and kidney diseases...
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2021 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...
DiaMedica Therapeutics to Report First Quarter 2021 Financials and Provide a Business Update May 6, 2021
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...
DiaMedica Therapeutics to Participate in the B. Riley Securities' Neuroscience Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...
New Strong Sell Stocks for April 20th
ATTO, DMAC, DG, GEL, and IAG have been added to the Zacks Rank #5 (Strong Sell) List on April 20, 2021
DiaMedica Therapeutics to Present Research at the National Kidney Foundation's 2021 Spring Clinical Meetings
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...
DiaMedica Therapeutics Announces 2020 Financial Results and Provides a Business Update
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...
DiaMedica Therapeutics to Present Research at International Stroke Virtual Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel recombinant proteins in the treatments for neurological and kidney d...
DiaMedica Therapeutics Hosting Key Opinion Leader Webinar on DM199 for Treatment of Acute Ischemic Stroke
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced tha...
DiaMedica Therapeutics to Participate at Upcoming Investor Conferences
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...
DiaMedica Therapeutics to Report Fourth Quarter 2020 Financials and Provide a Business Update March 11, 2021
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...